Table 5.
Univariate analysis of significant survival outcomes.
| Variables | 2-year rate (95% CI) | P |
|---|---|---|
| Leukemia-free survival | ||
| DRI: | ||
| Low | 87 (66–96) | <0.001 |
| Intermediate | 75 (65–82) | |
| High | 67 (53–77) | |
| Very high | 29 (8–55) | |
| 2017 ELN risk: | ||
| Favorable | 76 (59–86) | 0.01 |
| Intermediate | 76 (66–84) | |
| Adverse | 63 (52–72) | |
| Disease status at allo-HSCT: | ||
| Active disease | 40 (21–58) | <0.001 |
| CR/pos MRD | 73 (59–83) | |
| CR/neg MRD | 82 (71–90) | |
| CR/no MRD | 71 (58–81) | |
| HCT-CI: | ||
| <3 | 77 (70–85) | 0.02 |
| ≥3 | 62 (53–74) | |
| MRD status at 90 days: | ||
| Positive | 65 (46–91) | 0.04 |
| Negative | 86 (79–94) | |
| Overall survival | ||
| DRI: | ||
| Low | 96 (75–99) | <0.001 |
| Intermediate | 77 (68–84) | |
| High | 70 (57–80) | |
| Very high | 29 (8–54) | |
| 2017 ELN risk: | ||
| Favorable | 79 (62–89) | 0.03 |
| Intermediate | 79 (69–86) | |
| Adverse | 67 (55–76) | |
| Disease status at allo-HSCT: | ||
| Active disease | 43 (25–60) | <0.001 |
| CR/pos MRD | 78 (64–87) | |
| CR/neg MRD | 87 (77–93) | |
| CR/no MRD | 74 (61–83) | |
| HCT-CI: | ||
| <3 | 79 (71–86) | 0.03 |
| ≥3 | 69 (60–79) | |
| Graft-versus-host-free/relapse-free survival | ||
| DRI: | ||
| Low | 58 (37–74) | 0.002 |
| Intermediate | 53 (44–62) | |
| High | 40 (28–52) | |
| Very high | 8 (5–30) | |
| 2017 ELN risk: | ||
| Favorable | 55 (38–69) | 0.02 |
| Intermediate | 52 (42–62) | |
| Adverse | 37 (27–47) | |
| Disease status at allo-HSCT: | ||
| Active disease | 28 (14–44) | 0.01 |
| CR/pos MRD | 43 (30–56) | |
| CR/neg MRD | 55 (42–66) | |
| CR/no MRD | 51 (14–44) | |
y years, 95% CI 95% confidence interval, HR hazard ratio, DRI disease risk index, ELN European LeukemiaNet, allo-HSCT allogeneic hematopoietic stem cell transplant, HCT-CI hematopoietic cell transplantation-specific comorbidity index, CR complete remission, MRD minimal residual disease.